NCT05543174 - A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

October 25, 2023

Study Completion Date

July 25, 2025

Conditions

Alagille Syndrome (ALGS)

Interventions

DRUG

TAK-625

TAK-625 200 mcg or 400 mcg per kilogram, orally, once daily

Trial Locations (8)

University of Tsukuba Hospital, Tsukuba

Yokohamashi Tobu Hospital, Yokohama

Miyagi Children's Hospital, Sendai

Kindai University Nara Hospital, Ikoma

Osaka University Hospital, Suita

Juntendo University Hospital, Bunkyo-ku

Kyoto University Hospital, Kyoto

Saitama Prefectural Children's Medical Center, Saitama